BioGaia ABCHIX:BIOGBS 100 Dividend Yield % is 1.36% as of Jun. 27, 2026, which is 32% above its 10-year median of 1.03. GuruFocus rates CHIX:BIOGBS with a GF Score™ of 100/100 and a GF Value™ of kr129.06. The stock has 4 warning signs investors should review. Among 516 Drug Manufacturers companies, BioGaia AB ranks worse than 62.6% on this metric.
As of today (2026-06-27), the Trailing Annual Dividend Yield of BioGaia AB is 1.36%.
Warning Sign:
BioGaia AB stock Dividend Yield % is close to 1-year low.
The historical rank and industry rank for BioGaia AB's Dividend Yield % or its related term are showing as below:
CHIX:BIOGBs'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.55 Med: 1.03 Max: 2.85
Current: 1.36
During the past 13 years, the highest Dividend Yield of BioGaia AB was 2.85%. The lowest was 0.55%. And the median was 1.03%.
CHIX:BIOGBs's Dividend Yield % is ranked worse than 62.6% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.03
vs CHIX:BIOGBs: 1.36
During the past 12 months, BioGaia AB's average Dividends Per Share Growth Rate was 2.60% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 39.00% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 27.70% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 9.80% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of BioGaia AB was 66.40% per year. The lowest was -27.60% per year. And the median was 31.05% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
BioGaia AB (CHIX:BIOGBs) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for BioGaia AB's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
BioGaia AB Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
SEK 1.640000
2026-05-08
2026-05-11
2026-05-15
Cash Dividend
annually
SEK:SEK 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
BioGaia AB's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
1.64
/
120.20
=
1.36 %
Current Share Price is kr120.20. BioGaia AB's Dividends per Share for the trailing twelve months (TTM) ended in Today is kr1.64.
BioGaia AB's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
1.64
/
120.20
=
1.36 %
Current Share Price is kr120.20. BioGaia AB's Dividends per Share for the forward twelve months is calculated as kr1.64 * 1 = kr1.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (CHIX:BIOGBS) has a Dividend Yield % of 1.36% as of Jun. 27, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on BioGaia AB and its competitors. This is 32% above median its historical median of 1.03. Over the past decade, BioGaia AB's Dividend Yield % has ranged from 0.55 to 2.85. According to the industry distribution chart, BioGaia AB ranks #323 out of 516 companies in the Drug Manufacturers industry, placing it in the top 62.6%.
Is BioGaia AB's Dividend Yield % too high?
BioGaia AB's current Dividend Yield % of 1.36% is 32% above median its 10-year median of 1.03. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 2.85. The Drug Manufacturers industry median Dividend Yield % is 2.03. BioGaia AB's value of 1.36% is 33% below this industry median. Based on the distribution chart, BioGaia AB ranks #323 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #323 out of 516 companies for Dividend Yield %. This places BioGaia AB in the lower half of its industry. The industry median Dividend Yield % is 2.03. BioGaia AB's value of 1.36% is 33% below this benchmark. Historically, BioGaia AB's own Dividend Yield % has ranged from 0.55 to 2.85 over the past decade. While the company's 10-year median is 1.03 vs. the industry median of 2.03, BioGaia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.03, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Dividend Yield % of 1.36% is 33% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Dividend Yield % is 1.36%, which is 32% above median its own 10-year median of 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (CHIX:BIOGBS) has a current Dividend Yield % of 1.36%. The stock's GF Value™ is kr129.06, compared to a current price of kr120.20 — trading 6.9% below its estimated fair value. The current Dividend Yield % is 1.36%, which is 32% above median its 10-year median of 1.03 and 33% below the Drug Manufacturers industry median of 2.03. BioGaia AB's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For BioGaia AB (CHIX:BIOGBS), the current Dividend Yield % is 1.36% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (CHIX:BIOGBS) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of kr120.20 is trading 6.9% below its estimated GF Value™ of kr129.06.
Key valuation signals for CHIX:BIOGBS:
Dividend Yield %: 1.36% (32% above median its 10-year median of 1.03)
GF Value™: kr129.06 vs. price of kr120.20 (6.9% below fair value)
Industry Position: 33% below the Drug Manufacturers median (#323 of 516)
No single metric tells the full story. See the CHIX:BIOGBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for CHIX:BIOGBS
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BIOGBS has been successfully added to your 
